Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Uterine Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Breast Neoplasms 1

Interventions

Cyclophosphamide 77Paclitaxel 48Trastuzumab 40Tamoxifen 39Doxorubicin 37Docetaxel 35Radiotherapy 32Fluorouracil 26Chemotherapy, Adjuvant 26Taxes 23Epirubicin 22Carboplatin 22Filgrastim 21Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 19Neoadjuvant Therapy 18aldesleukin 16Peripheral Blood Stem Cell Transplantation 16Bevacizumab 13Lapatinib 12CMF regimen 12Anastrozole 12exemestane 11Goserelin 11Capecitabine 11Biopsy 11veliparib 10sargramostim 10fludarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms × 4-hydroxy-N-desmethyltamoxifen × Clear all
NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡